paclitaxel

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• Ultra-low doses could bring costly cancer treatments to more patients in poorer countries
  Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.
  stat · 2mo ago
• Immunotherapy Advances in Upfront SCAC Expose Need for Better Second-Line Strategies
  Aparna R. Parikh, MD, emphasizes the feasibility of immunotherapy trials in SCAC and the need for better treatment options in the second line and beyond.
  onclive · 3mo ago
• Five Under 5: Top Oncology Videos for the Week of 5/3
  The top 5 OncLive TV videos of the week cover insights in ovarian cancer, classical Hodgkin lymphoma, pancreatic cancer, melanoma, and myelofibrosis.
  onclive · 3mo ago
• Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCT
  R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.
  onclive · 3mo ago
• Dr Sznol on the Nuances of Recommending Neoadjuvant Therapy in Metastatic Melanoma
  Mario Sznol, MD, discusses current guidance around the use of neoadjuvant therapy in advanced melanoma.
  onclive · 3mo ago
• Dr Gruenbaum on Where Alternative Options to BTK Inhibitors Stand in MCL
  Lore Gruenbaum, PhD, discusses alternative treatments to BTK inhibitors like bispecific antibodies and CAR T-cell therapy in mantle cell lymphoma.
  onclive · 3mo ago
• Dr Sznol on Optimal Treatment Sequencing in Melanoma
  Mario Sznol, MD, discusses the challenges of determining whether to recommend adjuvant therapy for patients with melanoma based on current data.
  onclive · 3mo ago
• Dr Mauro on the Significance of Alternative TKI Formulations in CML
  Michael Mauro, MD, details the FDA approval of the small-molecule formulation of dasatinib and other alternate TKI formulations in chronic myeloid leukemia.
  onclive · 3mo ago
• Dr Olawaiye on the FDA Approval of Relacorilant Plus Nab-Paclitaxel in PROC
  Alexander B. Olawaiye, MD, discusses the clinical significance of the FDA approval of relacorilant plus nab-paclitaxel in PROC.
  onclive · 3mo ago
• Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer
  Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.
  onclive · 3mo ago